Pfizer's Covid product portfolio, Comnirnaty and Paxlovid, saw a surge in sales in the first half of 2025

Worldwide revenue (in millions USD) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for the top 10 Pfizer's marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: Pfizer's financial disclosuresDownload imageCreated with Datawrapper